
Annual report 2024
added 12-13-2025
Check-Cap Ltd. Long-Term Debt 2011-2025 | CHEK
Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.
Main characteristics:- Term exceeds 12 months
- Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
- Repaid through regular payments (interest and/or principal) over several years
- Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital. - Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks. - Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.
A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.
If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.
It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.
Examples of long-term debt:- Mortgage loans for property purchases
- Corporate bonds issued by a company to raise capital
- Project financing — long-term loans for building or expanding production facilities
- Leasing obligations for equipment or transport
Quarterly Long-Term Debt Check-Cap Ltd.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 795 K | - | 815 K | - | 125 K | - | 121 K | - | 211 K | - | 236 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 815 K | 121 K | 384 K |
Long-Term Debt of other stocks in the Diagnostics research industry
| Issuer | Long-Term Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
15.6 M | - | -6.23 % | $ 30.6 M | ||
|
Akumin
AKU
|
1.25 B | - | -17.87 % | $ 25.9 M | ||
|
Brainsway Ltd.
BWAY
|
2.08 M | $ 16.75 | -1.28 % | $ 99.4 M | ||
|
Burning Rock Biotech Limited
BNR
|
18.3 M | $ 16.9 | 7.3 % | $ 183 M | ||
|
Accelerate Diagnostics
AXDX
|
782 K | - | -61.36 % | $ 2.46 M | ||
|
Biocept
BIOC
|
1.2 M | - | -13.05 % | $ 7.29 M | ||
|
BioNano Genomics
BNGO
|
3.54 M | $ 1.57 | -3.08 % | $ 2 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
32 K | - | - | $ 562 M | ||
|
Castle Biosciences
CSTL
|
9.74 M | $ 38.44 | -0.5 % | $ 1.07 B | ||
|
DarioHealth Corp.
DRIO
|
24.6 M | $ 12.0 | 0.93 % | $ 340 M | ||
|
Chembio Diagnostics
CEMI
|
76.7 K | - | 0.22 % | $ 16.8 M | ||
|
DexCom
DXCM
|
58.6 M | $ 66.39 | -0.85 % | $ 25.6 B | ||
|
Danaher Corporation
DHR
|
15.5 B | $ 226.5 | - | $ 166 B | ||
|
Exact Sciences Corporation
EXAS
|
13.2 M | $ 101.57 | 0.07 % | $ 18.8 B | ||
|
Fulgent Genetics
FLGT
|
360 K | $ 26.81 | -1.22 % | $ 811 M | ||
|
Global Cord Blood Corporation
CO
|
147 K | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
54.2 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
388 K | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
5.49 M | - | 0.12 % | $ 80.1 M | ||
|
DermTech
DMTK
|
38 K | - | -11.32 % | $ 2.94 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
1.16 B | - | - | $ 10.7 B | ||
|
CareDx, Inc
CDNA
|
28.3 M | $ 19.74 | -3.99 % | $ 1.06 B | ||
|
Celcuity
CELC
|
105 M | $ 102.0 | -3.09 % | $ 4.02 B | ||
|
Enzo Biochem
ENZ
|
189 K | - | -8.98 % | $ 14.8 K | ||
|
Anixa Biosciences
ANIX
|
203 K | $ 3.53 | -1.4 % | $ 113 K | ||
|
Co-Diagnostics
CODX
|
2.15 M | $ 0.31 | -9.4 % | $ 9.1 M | ||
|
Quidel Corporation
QDEL
|
101 M | $ 28.81 | 0.03 % | $ 1.21 B | ||
|
IQVIA Holdings
IQV
|
12.8 B | $ 222.3 | 0.04 % | $ 40.3 B | ||
|
Guardant Health
GH
|
1.14 B | $ 103.47 | 1.37 % | $ 12.7 B | ||
|
Aspira Women's Health
AWH
|
2.32 M | - | -6.19 % | $ 10.5 M | ||
|
Heska Corporation
HSKA
|
307 K | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
546 K | - | -20.0 % | $ 1.06 M | ||
|
Illumina
ILMN
|
554 M | $ 133.88 | -0.73 % | $ 21.3 B | ||
|
Charles River Laboratories International
CRL
|
2.24 B | $ 196.14 | 1.64 % | $ 10.1 B | ||
|
Quotient Limited
QTNT
|
145 M | - | -11.32 % | $ 1.1 M | ||
|
Quest Diagnostics Incorporated
DGX
|
5.62 B | $ 183.36 | 0.47 % | $ 20.4 B | ||
|
Biodesix
BDSX
|
40 M | $ 7.56 | -3.63 % | $ 980 M | ||
|
Mettler-Toledo International
MTD
|
1.83 B | $ 1 410.24 | 1.17 % | $ 29.9 B | ||
|
Laboratory Corporation of America Holdings
LH
|
5.33 B | $ 262.29 | -0.71 % | $ 22 B | ||
|
Myriad Genetics
MYGN
|
39.6 M | $ 7.01 | -2.84 % | $ 635 M | ||
|
ICON Public Limited Company
ICLR
|
3.4 B | $ 183.39 | -1.71 % | $ 15.1 B | ||
|
IDEXX Laboratories
IDXX
|
450 M | $ 701.16 | -0.43 % | $ 57.8 B | ||
|
Lantheus Holdings
LNTH
|
565 M | $ 67.34 | 1.08 % | $ 4.66 B | ||
|
NeoGenomics
NEO
|
340 M | $ 12.07 | 1.81 % | $ 1.53 B | ||
|
Neogen Corporation
NEOG
|
875 M | $ 6.8 | -0.95 % | $ 1.47 B | ||
|
Agilent Technologies
A
|
2.73 B | $ 140.63 | 0.69 % | $ 42.8 B | ||
|
Biomerica
BMRA
|
100 K | $ 2.56 | 0.29 % | $ 5.88 M | ||
|
Bioventus
BVS
|
367 M | $ 7.59 | 0.53 % | $ 475 M | ||
|
Motus GI Holdings
MOTS
|
1.24 M | - | -34.28 % | $ 263 K |